---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-003388"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:36:22.991746+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Geron extends Pharmakon loan draw deadline to July 30, 2026; $125M already funded

## Summary
- First Amendment extends Tranche B ($75M) and Tranche C ($50M) request deadline from Dec 31, 2025 to July 30, 2026.
- Makewhole Date for prepayment extended from Nov 1, 2026 to May 1, 2027.
- Tranche A of $125M funded Nov 1, 2024; total facility remains up to $250M.
- Prepayment premiums unchanged: 3% before 3rd anniversary, 2% thereafter, 1% before maturity.

## SEC filing metadata
- accession: 0001193125-26-003388
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000119312526003388/0001193125-26-003388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000119312526003388/d88250d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-003388
- JSON: https://secwatch.observer/filing/0001193125-26-003388.json
- Plain text: https://secwatch.observer/filing/0001193125-26-003388.txt

## Key facts
- Material Agreements
  GERON CORP amended First Amendment to Loan Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership valued at Extended outside date for Tranche B and Tranche C loan availability from December 31, 2025 to July 3 (effective 2026-01-05).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership
  - Value: Extended outside date for Tranche B and Tranche C loan availability from December 31, 2025 to July 3
  - Effective: 2026-01-05
  source text: On January 5, 2026, Geron Corporation ("we" or the "Company") entered into that certain first amendment to loan agreement (the "First Amendment Agreement") with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a "Lender"), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent (the "Agent"), which amends the terms of that certain Loan Agreement, dated as of November 1, 2024 (the "Loan Agreement", and as amended by the First Amendment Agreement, the "Amended Loan Agreement), by and among the Company, the Lenders and the Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886744/000119312526003388/0001193125-26-003388-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.